Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
Source : https://www.medsci.org/v19p1118.htm
Int J Med Sci 2022; 19(7):1118-1121. doi:10.7150/ijms.72772 This issue Review Bo Liang 1,2, Ning Gu 3 1. Nanjing University of Chinese Medicine, Nanjing, China.2. Department of Cardiology, The Second Affiliated...
Relevance: Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations.
Association between Empagliflozin Use and Electrocardiographic Changes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35892445/
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use...
Conclusion: We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.
-
Heart Failure Connect4yrKey Points • Source: Clinics and Practice • Relevance: “Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) Show More
MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35900373/
Medium chain acyl-CoA dehydrogenase (MCAD) is one of the significant enzymes involved in β-oxidation of mitochondrial fatty acids. MCAD deficiency affects the β-oxidation of fatty acid and leads to lipid...
Conclusion/Relevance: Empagliflozin could upregulate MCAD expression by activating AMPK/FOXA2 signaling pathway, reduce lipid deposition and improve NASH in vivo and in vitro. This research demonstrated that MCAD is a key player of hepatic lipid deposition and it's targeting partially corrects NASH. MCAD thus may be a potential therapeutic...
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35887308/
1 Institute for Biomedicine and Health Sciences (HEALTH), Joanneum Research Forschungsgesellschaft m.b.H, Neue Stiftingtalstrasse 2, 8010 Graz, Austria. 2 Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca,...
Relevance: The cardio-reno-metabolic benefits of the SGLT2 inhibitors canagliflozin (cana), dapagliflozin (dapa), ertugliflozin (ertu), and empagliflozin (empa) have been demonstrated, but it remains unclear whether they exert different off-target effects influencing clinical profiles. We aimed to investigate the effects of SGLT2 inhibitors...
Resting Cardiac Power Predicts Adverse Outcome in Heart Failure Patients With Preserved Ejection Fraction: A Prospective Study
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.915918/full
BackgroundWe sought to explore the significance of resting cardiac power/mass in predicting adverse outcome in patients with heart failure with preserved ejection fraction (HFpEF).MethodsThis prospective cohort study included patients with...
Conclusion: Resting cardiac power determined by non-invasive echocardiography is independently associated with the risk of adverse outcomes in HFpEF patients and provides incremental prognostic information.